Glenmark gets USFDA nod for fingolimod capsules; shares gain 2%

Internet Desk | Updated on June 19, 2020

Glenmark Pharmaceuticals on Friday announced that it had been granted final approval by the United States Food & Drug Administration (USFDA) for Fingolimod capsules, 0.5 mg, the generic version of Gilenya1 capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.

According to IQVIATM sales data for the 12 months ending April 2020, the Gilenya capsules, 0.5 mg market achieved annual sales of approximately $2.1 billion.

Shares of the company trade over 2 per cent higher at Rs 417.

Published on June 19, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like